Last reviewed · How we verify
NCT04225429
Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma
trial testing Tazemetostat in Epithelioid Sarcoma. No longer available.
Quick facts
| Lead sponsor | Epizyme, Inc. |
|---|---|
| Status | NO LONGER AVAILABLE |
| Study type | EXPANDED_ACCESS |
Drugs / interventions tested
- Tazemetostat (tazemetostat) — full drug profile →
Conditions studied
- Epithelioid Sarcoma — all drugs for Epithelioid Sarcoma →
Sponsor
Epizyme, Inc. — full company profile →
Who can join
18 and older, any sex, with Epithelioid Sarcoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A multicenter, open-label expanded access program to provide access to tazemetostat to Epithelioid Sarcoma (ES) patients in serious need who are otherwise unable to participate in a clinical study or whom access is not available through marketed product in the US.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
The roles of EZH2 in cancer and its inhibitors.
Liu Y, Yang Q. · · 2023 · cited 100× · PMID 37148376 · DOI 10.1007/s12032-023-02025-6 -
The cancer epigenome: Non-cell autonomous player in tumor immunity.
Kato S, Maeda Y, Sugiyama D, Watanabe K, et al · · 2023 · cited 3× · PMID 36468774 · DOI 10.1111/cas.15681 -
Targeting epigenetic methylation: emerging diagnosis and therapeutic strategies in cancer.
Zhu Y, Liu K, Zhu H. · · 2026 · PMID 41673722 · DOI 10.1186/s40164-026-00760-w
Verify or expand the search:
- PubMed search for NCT04225429
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tazemetostat
Trials testing the same drug.
- NCT06575686 — Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma · Phase 2 · suspended
- NCT06692452 — Tazemetostat Plus CHOP in 1L T-cell Lymphoma · Phase 2 · withdrawn
- NCT06242834 — Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggres · Phase 2 · active not recruiting
- NCT05983965 — Study of Tazemetostat in Lymphoid Malignancies · Phase 1 · terminated
- NCT05151588 — Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal Carcinoma · Phase 2 · not yet recruiting
Other recruiting trials for Epithelioid Sarcoma
Currently open trials in the same condition.
- NCT05407441 — Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors · Phase 1, PHASE2 · active not recruiting
- NCT05286801 — Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors · Phase 1, PHASE2 · active not recruiting
- NCT04390737 — Evaluate the Safety and Clinical Activity of HH2853 · Phase 1, PHASE2 · recruiting
- NCT03099681 — An Observational Study on Epithelioid Sarcoma · recruiting
- NCT02180867 — Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly D · Phase 2, PHASE3 · active not recruiting
Other Epizyme, Inc. trials
Trials by the same sponsor.
- NCT06068881 — A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lym · Phase 2 · withdrawn
- NCT05121103 — A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With R · Phase 1 · terminated
- NCT05205252 — A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. · Phase 1, PHASE2 · withdrawn
- NCT04762160 — SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicula · Phase 2 · terminated
- NCT04224493 — A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenal · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04225429 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Epizyme, Inc.
- Last refreshed: 1 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04225429.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing